List of Studies

Back
Study IDStudy TitleLanguage Clinical Study Result Plain Language Summary
2215-CL-0101A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia. English


English


2215-CL-0102A Phase 1 Open-label, Dose-escalation Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia English


English


2215-CL-0105A Phase 1 Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients with Advanced Solid Tumors English


English


2215-CL-5101A Phase 1b/2 Study of ASP2215 in Combination with Erlotinib in Subjects with EGFR Activating Mutation-Positive (EGFRm+) Advanced NSCLC Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) English


English


QUICK SEARCH

USEFUL LINKS